Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 1/20 | 0.63 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bicarbonate SCHEMBL29983911 | 0.98 | ESR1 (0.61) | ESR1ESR2KMT2AHCRTR1MAPT | |
| SCHEMBL21986971 | 0.94 | ESR1 (0.57) | ESR1ESR2KMT2AHCRTR1MAPT | |
| SCHEMBL4392103 | 0.89 | ESR1 (0.62) | ESR1ESR2KMT2AHCRTR1MAPT | |
| SCHEMBL4343858 | 0.88 | ESR1 (0.51) | ESR1ESR2KMT2AHCRTR1MAPT | |
| SCHEMBL11823799 | 0.87 | ESR1 (0.53) | ESR1ESR2KMT2AHCRTR1MAPT | |
| SCHEMBL26125296 | 0.87 | ALDH1A1 (0.55) | ESR1ESR2KMT2AMAPTHSD17B10 | |
| SCHEMBL28468927 | 0.87 | ESR1 (0.51) | ESR1ESR2KMT2AHCRTR1MAPT | |
| Bicarbonate SCHEMBL7114860 | 0.86 | ESR1 (0.50) | ESR1ESR2KMT2AHCRTR1MAPT | |
| Bicarbonate SCHEMBL29983692 | 0.86 | ALDH1A1 (0.54) | ESR1ESR2KMT2AMAPTHSD17B10 | |
| SCHEMBL4395023 | 0.86 | MAPT (0.56) | ESR1ESR2KMT2AMAPTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 596 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581114-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Novozymes A/S (DK) | 2025-07-09 | — | — | EP | claimed |
| US-20250163343-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | INTERNATIONAL FLAVORES & FRAGRANCES INC. | 2025-05-22 | — | — | US | claimed |
| EP-4486857-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | International Flavors & Fragrances Inc. (US) | 2025-01-08 | — | — | EP | claimed |
| US-12037461-B2 | Encapped curable polyorganosiloxanes | HENKEL AG & CO. KGAA (DE) | 2024-07-16 | — | — | US | claimed |
| WO-2024046952-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | NOVOZYMES A/S (DK) | 2024-03-07 | — | — | WO | claimed |
| WO-2023168069-A1 | FRAGRANCE COMPOSITIONS FOR SLEEP IMPROVEMENT | INTERNATIONAL FLAVORS & FRAGRANCES INC. (US) | 2023-09-07 | — | — | WO | claimed |
| EP-3660116-B1 | ENDCAPPED CURABLE POLYORGANOSILOXANES | HENKEL AG & CO KGAA (DE) | 2023-07-26 | — | — | EP | claimed |
| US-20200048578-A1 | ORGANIC COMPOUNDS | GIVAUDAN S.A. (CH) | 2020-02-13 | — | — | US | claimed |
| US-20180051231-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2018-02-22 | — | — | US | claimed |
| EP-3271443-A1 | IMPROVEMENTS IN OR RELATING TO ORGANIC COMPOUNDS | Givaudan SA (CH) | 2018-01-24 | — | — | EP | claimed |
| WO-2008113495-A2 | PERFUME COMPOSITIONS | GIVAUDAN NEDERLAND SERVICES B.V. (NL) | 2008-09-25 | — | — | WO | claimed |
| EP-1928406-A2 | PHARMACEUTICAL COMPOSITIONS WITH MELTING POINT DEPRESSANT AGENTS AND METHOD OF MAKING SAME | Antares Pharma IPL AG (CH) | 2008-06-11 | — | — | EP | claimed |
| US-20070166341-A1 | Solid volatile composition and method and system for making the same | INTERNATIONAL ARTS & SCIENCE GROUP, INC. | 2007-07-19 | — | — | US | claimed |
| WO-2007022924-A2 | PHARMACEUTICAL COMPOSITIONS WITH MELTING POINT DEPRESSANT AGENTS AND METHOD OF MAKING SAME | ANTARES PHARMA IPL AG (CH) | 2007-03-01 | — | — | WO | claimed |
| US-20070048360-A1 | Pharmaceutical compositions with melting point depressant agents and method of making same | ANTARES PHARMA IPL AG (CH) | 2007-03-01 | — | — | US | claimed |
| US-6555098-B1 | Fragrance crystallites in the form of polymer surface-coated particles | CHURCH & DWIGHT CO., INC. | 2003-04-29 | — | — | US | claimed |
| WO-1998056337-A1 | MALODOR REDUCING COMPOSITION CONTAINING AMBER AND MUSK MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 1998-12-17 | — | — | WO | claimed |
| WO-1997030686-A1 | COSMETIC DEODORANT PRODUCTS CONTAINING ENCAPSULATED BICARBONATE AND FRAGRANCE INGREDIENTS | CHURCH & DWIGHT COMPANY, INC. (US) | 1997-08-28 | — | — | WO | claimed |
| WO-1997011677-A1 | COSMETIC DEODORANT PRODUCTS CONTAINING A POLYMER/FRAGRANCE-ENCAPSULATED BICARBONATE INGREDIENT | CHURCH & DWIGHT COMPANY, INC. (US) | 1997-04-03 | — | — | WO | claimed |
| US-5614179-A | Cosmetic deodorant products containing a polymer/fragrance-encapsulated bicarbonate ingredient | CHURCH & DWIGHT CO., INC. (US) | 1997-03-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070048360-A1 | Pharmaceutical compositions with melting point depressant agents and method of making same | TRPA1, TRPV1, OR51E2 | ESR1 3823/4885ESR2 3404/4885KMT2A 3758/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.